Currently Enrolling Trials
Vabysmo (faricimab-svoa) - 3 indications
- for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration and Diabetic Macular Edema; approved January of 2022
- for the treatment of macular edema following retinal vein occlusion; approved October of 2023
Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor.
Vabysmo is specifically indicated:
- for the treatment of patients with Neovascular (wet) Age-Related Macular Degeneration (nAMD)
- for the treatment of patients with Diabetic Macular Edema
- for the treatment of patients with macular edema following retinal vein occlusion
Vabysmo (faricimab-svoa) is supplied as a solution for intravitreal injection. Each vial should only be used for the treatment of a single eye. Scroll down for recommended dosing for each indication.
Mechanism of Action
Vabysmo (faricimab-svoa) is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD and DME. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD and DME has yet to be established.
The most common adverse effect associated with the use of Vabysmo was conjunctival hemorrhage.
Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition.